D
Overview
Dashlabs.ai helps clinics, labs, and hospitals run smarter by automating labor-intensive laboratory workflows to lower costs and speed up operations. Its software digitizes and coordinates lab tasks, allowing teams to work faster while improving patient experience. The company differentiates itself by targeting day-to-day lab automation with clear efficiency gains and seamless integration into existing healthcare environments. Its goal is to accelerate healthy access to care by making laboratory operations simpler, faster, and cheaper for timely diagnostics and treatment.
Work here?Claim your company
Simplify's take
What believers are saying
- Dashlabs claims 350-plus organizations and 20 million-plus patients processed by 2026.
- Pricing changed September 6, 2026, showing active monetization and demand testing.
- The company now sells in the Philippines, Indonesia, and Malaysia, widening expansion runway.
What critics are saying
- Leadership is unsettled: 2026 databases still split between Weston Coleman Lim and Bryan Giger.
- Company metrics conflict; its own site and third parties disagree on countries and scale.
- Last funding dates to 2021, leaving a tiny war chest against larger LIS competitors.
What makes Dashlabs.ai unique
- Dashlabs bundles LIS, EHR, billing, queueing, and machine integration for Southeast Asian labs.
- Workflow and Queue centralize clinic routing, reducing manual handoffs across stations.
- Its Philippines-first model targets fragmented diagnostics markets ignored by larger global software vendors.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Industry standards
Ind Avg. $3.3M
$130k
$500k
$1.5M
$2M
$2.3M
$3M